pyrazines has been researched along with as 3201 in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 17 (60.71) | 29.6817 |
| 2010's | 9 (32.14) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Fujitani, B; Komiya, M; Kuromiya, A; Matsumoto, J; Murata, M; Negoro, T; Ono, Y; Suzuki, K; Ueda, S | 1 |
| Fujiwara, I; Kurono, M; Yoshida, K | 1 |
| Fujii, T; Kamataki, T; Terauchi, Y; Toide, K; Yamazaki, H | 1 |
| Bril, V; Buchanan, RA | 2 |
| Nakamura, J | 1 |
| Hotta, N | 1 |
| Fujii, A; Fujitani, B; Kurono, M; Murata, M; Negoro, T | 1 |
| Giannoukakis, N | 3 |
| Itogawa, A; Kurono, M; Noguchi, H; Sanjoba, M | 1 |
| Fujiwara, Y; Hara, K; Kumagai, N; Mashiko, T; Shibasaki, M; Tanaka, D | 1 |
| Kumagai, N; Mashiko, T; Shibasaki, M | 2 |
| Bril, V; Kuromiya, A; Matsumoto, T; Ono, Y; Toyosawa, K; Ueda, Y | 1 |
| Bril, V; Kuromiya, A; Kurono, M; Matsumoto, T; Nakamura, K; Ono, Y | 2 |
| Bril, V; Buchanan, R; Hirose, T; Tomioka, S | 1 |
| Dong, G; Osipov, M; Trost, BM | 1 |
| Kakehashi, A; Kinoshita, N; Matsumoto, T; Ota, A; Shimmura, M; Takano, H; Tanaka, Y; Toyoda, F; Tsuji, J | 1 |
| Arezzo, J; Bradshaw, KL; Bril, V; Gordon, RJ; Junor, RW; Nash, M; Polydefkis, M; Shaibani, A | 1 |
| Kohara, N; Satoh, J; Sekiguchi, K; Yamaguchi, Y | 1 |
| Atsumi, T; Ishizu, A; Kusunoki, Y; Miyoshi, A; Miyoshi, H; Nakamura, A; Nakazawa, D; Shida, H; Tomaru, U; Yamada, M | 1 |
| Ishibashi, Y; Kato, H; Matsui, T; Matsumoto, T; Yamagishi, S | 1 |
| Baba, M; Hamatani, T; Imai, T; Kohara, N; Komori, T; Naito, Y; Satoh, J; Sekiguchi, K; Yamaguchi, Y | 1 |
| Kita, S; Tsuzaki, K; Yamamura, ET | 1 |
| Fujita, T; Inoue, K; Ishii, D; Itou, M; Kakuyama, H; Takagaki, T; Uchida, N | 1 |
6 review(s) available for pyrazines and as 3201
| Article | Year |
|---|---|
[Role of polyol pathway in pathogenesis of diabetic microangiopathy].
Topics: Aldehyde Reductase; Animals; Diabetic Angiopathies; Fructose; Glucose; Glycation End Products, Advanced; Humans; L-Iditol 2-Dehydrogenase; Oxidative Stress; Polymers; Polymorphism, Genetic; Protein Kinase C; Pyrazines; Sorbitol; Spiro Compounds | 2005 |
[Progress on the drug therapy for diabetic microangiopathies: aldose reductase inhibitor].
Topics: Aldehyde Reductase; Animals; Clinical Trials as Topic; Diabetic Angiopathies; Drug Design; Humans; Imidazolidines; Polymers; Polymorphism, Genetic; Pyrazines; Rhodanine; Spiro Compounds; Thiazolidines | 2005 |
Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications.
Topics: Aldehyde Reductase; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Contraindications; Diabetes Complications; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Pyrazines; Spiro Compounds; Structure-Activity Relationship | 2006 |
Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications.
Topics: Aldehyde Reductase; Animals; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Enzyme Inhibitors; Humans; Pyrazines; Sorbitol; Spiro Compounds; Treatment Outcome | 2008 |
Inventing and understanding catalytic, enantioselective reactions.
Topics: Aldehyde Reductase; Amination; Catalysis; Chemistry, Pharmaceutical; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Hydrogenation; Hypoglycemic Agents; Models, Chemical; Molecular Structure; Pyrazines; Sitagliptin Phosphate; Spiro Compounds; Stereoisomerism; Triazoles | 2009 |
Evaluation of ranirestat for the treatment of diabetic neuropathy.
Topics: Aldehyde Reductase; Animals; Biomarkers; Clinical Trials as Topic; Diabetic Neuropathies; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Mice; Pyrazines; Rats; Reproducibility of Results; Spiro Compounds | 2014 |
7 trial(s) available for pyrazines and as 3201
| Article | Year |
|---|---|
Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy.
Topics: Adolescent; Adult; Aged; Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electromyography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neural Conduction; Polyneuropathies; Probability; Pyrazines; Reference Values; Risk Assessment; Severity of Illness Index; Spiro Compounds; Sural Nerve; Treatment Outcome | 2004 |
Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
Topics: Aldehyde Reductase; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Enzyme Inhibitors; Glycated Hemoglobin; Humans; Motor Neurons; Neural Conduction; Patient Selection; Peripheral Nerves; Peroneal Nerve; Placebos; Pyrazines; Spiro Compounds; Sural Nerve | 2006 |
Ranirestat for the management of diabetic sensorimotor polyneuropathy.
Topics: Adolescent; Adult; Aged; Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Median Nerve; Middle Aged; Motor Neurons; Neural Conduction; Placebos; Pyrazines; Sensory Thresholds; Spiro Compounds; Sural Nerve; Young Adult | 2009 |
Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy.
Topics: Aged; Diabetic Neuropathies; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neural Conduction; Polyneuropathies; Pyrazines; Quality of Life; Spiro Compounds; Treatment Outcome | 2015 |
Effect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study.
Topics: Administration, Oral; Aged; Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Japan; Kidney Function Tests; Liver Function Tests; Male; Middle Aged; Motor Neurons; Neural Conduction; Pyrazines; Sensory Receptor Cells; Severity of Illness Index; Spiro Compounds; Temperature | 2016 |
Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.
Topics: Adult; Aged; Aldehyde Reductase; Diabetic Neuropathies; Double-Blind Method; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Neural Conduction; Prognosis; Pyrazines; Quality of Life; Spiro Compounds; Young Adult | 2019 |
Pharmacokinetics and Safety of Ranirestat in Patients With Hepatic Impairment.
Topics: Adult; Aged; Area Under Curve; Diabetic Neuropathies; Enzyme Inhibitors; Female; Healthy Volunteers; Humans; Liver Diseases; Male; Middle Aged; Protein Binding; Pyrazines; Spiro Compounds | 2020 |
15 other study(ies) available for pyrazines and as 3201
| Article | Year |
|---|---|
Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.
Topics: Aldehyde Reductase; Animals; Crystallography, X-Ray; Diabetes Mellitus, Experimental; Enzyme Inhibitors; In Vitro Techniques; Lens, Crystalline; Male; Molecular Conformation; Pyrazines; Rats; Rats, Wistar; Sciatic Nerve; Sorbitol; Spiro Compounds; Stereoisomerism; Structure-Activity Relationship; Swine | 1998 |
Stereospecific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS-3201, with aldose reductase.
Topics: Aldehyde Reductase; Binding Sites; Bromosuccinimide; Enzyme Inhibitors; Enzyme Stability; Fluorine; Holoenzymes; Humans; Hydrogen-Ion Concentration; Kinetics; Ligands; Models, Molecular; Nuclear Magnetic Resonance, Biomolecular; Pyrazines; Spectrometry, Fluorescence; Spiro Compounds; Stereoisomerism; Substrate Specificity; Succinimides; Temperature; Titrimetry | 2001 |
Uridine diphosphate sugar-selective conjugation of an aldose reductase inhibitor (AS-3201) by UDP-glucuronosyltransferase 2B subfamily in human liver microsomes.
Topics: Aldehyde Reductase; Glucuronosyltransferase; Humans; Isoenzymes; Microsomes, Liver; Pyrazines; Recombinant Proteins; Spiro Compounds; Uridine Diphosphate Glucose | 2004 |
Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: a significant role of specific binding by serum albumin in the improved potency and stability.
Topics: Aldehyde Reductase; Animals; Binding, Competitive; Blood Proteins; Enzyme Inhibitors; Fatty Acids, Nonesterified; Humans; Hydrogen-Ion Concentration; Hydrolysis; In Vitro Techniques; Kinetics; Ligands; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Organ Specificity; Protein Binding; Pyrazines; Rats; Serum Albumin; Spectrometry, Fluorescence; Spiro Compounds; Stereoisomerism; Temperature; Tissue Distribution | 2006 |
Stability and hydrolysis kinetics of spirosuccinimide type inhibitors of aldose reductase in aqueous solution and retardation of their hydrolysis by the target enzyme.
Topics: Aldehyde Reductase; Diabetes Complications; Drug Stability; Enzyme Inhibitors; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Osmolar Concentration; Pyrazines; Solutions; Spiro Compounds | 2008 |
En route to an efficient catalytic asymmetric synthesis of AS-3201.
Topics: Aldehyde Reductase; Amination; Catalysis; Hypoglycemic Agents; Molecular Structure; Pyrazines; Spiro Compounds | 2007 |
An improved lanthanum catalyst system for asymmetric amination: toward a practical asymmetric synthesis of AS-3201 (Ranirestat).
Topics: Amination; Catalysis; Lanthanum; Molecular Structure; Pyrazines; Spectrometry, Mass, Electrospray Ionization; Spiro Compounds; Stereoisomerism | 2008 |
Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats.
Topics: Aldehyde Reductase; Animals; Cataract; Diabetic Neuropathies; Enzyme Inhibitors; Pyrazines; Rats; Spiro Compounds | 2008 |
Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats.
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus; Diabetic Neuropathies; Enzyme Inhibitors; Male; Neural Conduction; Pyrazines; Rats; Rats, Wistar; Sorbitol; Spiro Compounds; Streptozocin | 2008 |
Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux.
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus, Experimental; Erythrocytes; Fructose; In Vitro Techniques; Male; Neural Conduction; Pyrazines; Rats; Rats, Wistar; Sciatic Nerve; Sorbitol; Spiro Compounds | 2009 |
A concise enantioselective synthesis of (-)-ranirestat.
Topics: Aldehyde Reductase; Molecular Structure; Pyrazines; Spiro Compounds; Stereoisomerism | 2010 |
Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats.
Topics: Administration, Oral; Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetic Retinopathy; Disease Models, Animal; Drug Administration Schedule; Enzyme Inhibitors; Glial Fibrillary Acidic Protein; Glycated Hemoglobin; Male; Neuroprotective Agents; Pyrazines; Rats; Rats, Sprague-Dawley; Retina; Rhodanine; Spiro Compounds; Thiazolidines; Time Factors | 2014 |
Circulating Neutrophil Extracellular Trap Levels in Well-Controlled Type 2 Diabetes and Pathway Involved in Their Formation Induced by High-Dose Glucose.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; DNA; Dose-Response Relationship, Drug; Extracellular Traps; Glucose; Humans; Hypoglycemic Agents; Middle Aged; Neutrophils; Peroxidase; Polymers; Pyrazines; Pyrroles; Quinazolines; Risk Factors; Spiro Compounds; Time Factors | 2016 |
Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose-exposed endothelial cells.
Topics: Aldehyde Reductase; Anti-Inflammatory Agents; Cell Line, Tumor; Chromatography, Liquid; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glucose; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Inflammation Mediators; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Rhodanine; Sorbitol; Spiro Compounds; Superoxides; Tandem Mass Spectrometry; Thiazolidines; Vascular Cell Adhesion Molecule-1 | 2016 |
A novel method of producing the key intermediate ASI-2 of ranirestat using a porcine liver esterase (PLE) substitute enzyme.
Topics: Amino Acid Sequence; Animals; Bacillus thuringiensis; Bacterial Proteins; Base Sequence; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Escherichia coli; Esterases; Hydrolysis; Liver; Pyrazines; Recombinant Proteins; Spiro Compounds; Swine | 2019 |